Ann: Preliminary Top-line Results from SMARTCOUGH-C Study, page-297

Firstly, Sincere commiserations to all holders. We are not the true people who will end up paying the price of this technology not getting off the ground.

Full Disclosure I have taken out most of my funds from this investment. I was extremely fortunate to have been in this as low as 1.6c from almost three years ago. It is time to move on.

I can't see this is worth the current market capitalisation with so little cash on hand, although it may be traded back to 10c or so. These trials, took painstakingly long to complete let alone initiate and they made an absolute meal out of the data collection. I can't see this turning around and them retraining the algorithms anytime soon.

Even if FDA is submitted for bronchitis, which Telehealth company would take this on as a single feature with only 46 patients tested.

Amazingly they are deciding to continue with US adult trials and prepare a second trial to run in conjunction. This will go on for another year at the bare minimum with another CR well on the cards. I will take a look at this next year.

I will 100% stick by my comment of the company was cheap at 30c - although this was contingent on the technology actually working. A factor many of us long term RAP holders though was a done deal due to the clinical evidence seen in Australia.

Clearly we were misled.